Okayama University

Other

Hamamatsu-photonics K.k.

Astellas Pharma Gmbh

Mamoru Ouchida

Iori Ohmori

Toshifumi Ozaki

Sachio Ito

Tatsuo Ito

Tomoji Mashimo

Takami Kondo

Takashi Oka

Tadashi Yoshino

Provided is a nonhuman animal model that is obtained by modifying a gene encoding thioredoxin and useful as a disease model of aging, kidney diseases, cardiovascular diseases, hypertension, aortic dissection, chronic obstructive lung disease, age-dependent epilepsy, abnormality of lipid metabolism, anemia, osteoporosis, abnormal immunity, etc. These variety of phenotypes are caused by the fact that a modification of a gene encoding thioredoxin induces hypofunction of thioredoxin expressed in multiple organs throughout the body. The gene encoding thioredoxin is a gene selected from among TXN, TRX, TRX1, RRDX, Txn1, Txn, Trx1 and ADF.

Genetically modified rat that expresses an F54L Txn1 mutant

Provided is a detection kit for detecting target genes of miRNA. Also provided is a method of detecting target genes of miRNA in a simple manner without the need for performing a transfection operation of a gene into cells via a vector. The detection kit is a detection kit for target genes of microRNA, including a cell extraction reagent, and a labeling reagent for microRNA or labeled microRNA, and further including a reaction reagent for the labeling substance for microRNA. mRNA corresponding to target genes of miRNA can be easily pulled down by producing a cell extract under mild conditions, adding labeled miRNA to the cell extract, and recovering the labeling substance. cDNA is produced from the pulled down mRNA to detect target genes of miRNA.

Method for detection of genes targeted by microRNA

Provided is a method of assessing a potential for development of Dravet syndrome with high accuracy, and use thereof. The method according to the present invention of assessing a potential for development of Dravet syndrome includes, with use of a sample taken from a subject, detecting whether or not a mutation is on &#x3b1;-subunit type 1 of voltage-gated sodium ion channel Na1.1, and detecting whether or not a mutation is on &#x3b1;-subunit type 1 of voltage-gated calcium ion channel Ca2.1.

Method for assessment of potential for development of dravet syndrome and use thereof

A therapeutic agent for soft tissue sarcoma (particularly synovial sarcoma), contains a histone deacetylase inhibitor (particularly a compound of formula I) as an active ingredient 

Therapeutic agent for soft tissue sarcoma

Growing community of inventors

Okayama, Japan

Mamoru Ouchida